Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
Family history of premature cardiovascular disease in a first-degree relative (before 45 years old in male relatives and before 55 years old in female relatives)
Use of chemotherapy, radiation therapy, or immunotherapy for breast cancer treatment
Thyroid-stimulating hormone (TSH) ≥ 7 with low free thyroxine (T4)
Hemoglobin \< 11 mg/dL
Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignancy, or uncontrolled psychiatric disease
Other anti-obesity medication used within the past 3 months
Prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty performed \> 1 year before screening)
Past or intended endoscopic and/or device-based therapy or removal within the last six months
Current or recent (within 3 months) use of medications that may cause weight gain, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers
Current or recent use (within 3 months) of systemic glucocorticoid therapy for over 2 weeks
Contraindications to glucagon-like peptide 1 (GLP-1) receptor agonist therapy
Currently enrolled in another clinical study involving an investigational product or participated in one and received treatment (active or placebo) in the last 30 days
Clareo Health | Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
